Three therapeutic antibodies have been approved for the treatment of severe asthma with eosinophilic inflammation: mepolizumab and reslizumab (anti-IL-5 antibodies) as well as benralizumab (antibody against the α-chain of the human IL-5 receptor (IL-5Rα)). Here, IL5 is linked to asthma.